Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan

BACKGROUND: Carfilzomib is a selective proteasome inhibitor approved for treating relapsed or refractory multiple myeloma (RRMM). Carfilzomib improves overall survival (OS) and progression‐free survival (PFS); however, treatment with carfilzomib results in a higher incidence of cardiovascular and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagiwara, Hiromi, Nakayama, Takafumi, Hashimoto, Hiroya, Kusumoto, Shigeru, Fukuta, Hidekatsu, Kamiya, Takeshi, Ikuta, Koichi, Iida, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587963/
https://www.ncbi.nlm.nih.gov/pubmed/37750384
http://dx.doi.org/10.1002/cam4.6457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587963/
https://www.ncbi.nlm.nih.gov/pubmed/37750384
http://dx.doi.org/10.1002/cam4.6457

Ejemplares similares